An expert discusses the FDA approval of Enhertu in unresectable or metastatic HR+, HER2-low or -ultralow breast cancer: © stock.adobe.com On Jan. 27, the Food and Drug Administration (FDA) granted approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for patients with unresectable or […]
Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer Read More »
The FDA granted ODD to OPN-6602 for relapsed or refractory multiple myeloma: © stock.adobe.com The Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the oral small molecule inhibitor OPN-6602 for the treatment of patients with relapsed
The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma Read More »
Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to TURBT was beneficial: © pikovit – stock.adobe.com Among patients with suspected muscle-invasive bladder cancers (MIBCs), the incorporation of magnetic resonance imaging (mpMRI) for initial staging prior
mpMRI Improves Initial Staging in Suspected Muscle-Invasive Bladder Cancer Read More »
Patients with gastrointestinal stromal tumors are significantly impacted by GI bleeding. | Crytal Light – stockadobe.com The prognosis of patients with gastrointestinal stromal tumors (GISTs) is significantly impacted by gastrointestinal (GI) bleeding, according to research from a systematic review and
GI Bleeding Significantly Impacts GIST Treatment Outcomes Read More »
The FIRCE-1 trial of firi-cel in relapsed/refractory large B-cell lymphoma has been discontinued. | nobeastsofierce – stock.adobe.com. The phase 2 FIRCE-1 clinical trial investigating treatment with the CAR T-cell therapy firicabtagene autoleucel (firi-cel) in patients with large B-cell lymphoma (LBCL)
Phase 2 Trial of Firi-Cel CAR T-Cell Therapy Discontinued in Lymphoma Read More »
High pre-HIFU PSA levels in intermediate-risk prostate cancer were linked to increased recurrence and treatment failure, per ASCO 2025 research. Among patients with intermediate-risk prostate cancer, high prostate-specific antigen (PSA) levels before treatment with a High-Intensity Focused Ultrasound (HIFU) had
Elevated PSA Link to Higher Recurrence Risk in Intermediate-Risk Prostate Cancer Read More »
Updated data from studies like EV-302 and CheckMate 274 were presented at the 2025 ASCO Genitourinary Cancers Symposium, reinforcing the role of their respective therapies among patients with urothelial carcinoma, according to Dr. Guru P Sonpavde. Sonpavde sat down for
An Expert Explains Updated Data For Patients With GU Cancers Read More »
FDA grants priority review to an NDA for taletrectinib in ROS1+ NSCLC. The Food and Drug Administration (FDA) has accepted a new drug application (NDA) with priority review for the investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib in the
FDA Accepts New Drug Application For Taletrectinib in ROS1+ NSCLC Read More »
The FDA has accepted an NDA for avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer. A new drug application (NDA) has been accepted by the Food and Drug Administration (FDA) under the accelerated approval pathway for the combination
The FDA recently granted a breakthrough therapy designation to Jemperli for certain patients with rectal cancer. Treatment with Jemperli (dostarlimab-gxly) has received a breakthrough therapy designation (BTD) from the Food and Drug Administration (FDA) for patients with locally advanced mismatch
FDA Grants Jemperli Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer Read More »
